Cornerstone Therapeutics (Nasdaq: CRTX ) is expected to report Q2 earnings around Aug. 4. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cornerstone Therapeutics' revenue will wither 32.8% and EPS will shrink to a loss.
The average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is -$0.02.
Last quarter, Cornerstone Therapeutics logged revenue of $22.2 million. GAAP reported sales were 26% lower than the prior-year quarter's $30.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.05. GAAP EPS were -$0.07 for Q1 compared to $0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.8%, 570 basis points worse than the prior-year quarter. Operating margin was -20.5%, 2,900 basis points worse than the prior-year quarter. Net margin was -8.2%, 1,400 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $80.1 million. The average EPS estimate is $0.10.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 107 members out of 111 rating the stock outperform, and four members rating it underperform. Among 19 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give Cornerstone Therapeutics a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cornerstone Therapeutics is buy, with an average price target of $12.00.
Over the decades, small-cap stocks like Cornerstone Therapeutics have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.